Copyright
©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Aug 10, 2011; 2(8): 303-310
Published online Aug 10, 2011. doi: 10.5306/wjco.v2.i8.303
Published online Aug 10, 2011. doi: 10.5306/wjco.v2.i8.303
Figure 1 Circulating tumor cell and metastatic process.
EMT: Epithelial-mesenchymal transition; CTC: Circulating tumor cell; DTC: Disseminated tumor cell; MET: Mesenchymal-epithelial transition.
Figure 2 Identification of tumor cells and white blood cells using monoclonal antibodies.
EpCAM: Epithelial-cell adhesion molecule; DAPI: 4’,6-diamidino-2-phenylindole.
Figure 3 Measurement of circulating tumor cells by the CellSearch® System.
CTC: Circulating tumor cell; DAPI: 4’,6-diamidino-2-phenylindole; CK: Cytokeratins; PE: Phycoerythrin.
Figure 4 Kaplan-Meier estimates of probabilities of progression-free survival in patients with metastatic breast cancer who had less than 5 circulating tumor cells and those who had 5 or more circulating tumor cells (before initiation of a new line of therapy)[29].
CTC: Circulating tumor cell.
Figure 5 Kaplan-Meier estimates of probabilities of overall survival in patients with metastatic breast cancer who had less than 5 circulating tumor cells and those who had 5 or more circulating tumor cells (before initiation of a new line of therapy)[29].
CTC: Circulating tumor cell.
Figure 6 Kaplan-Meier estimates of probabilities of progression-free survival in patients with metastatic breast cancer who had less than 5 circulating tumor cells and those who had 5 or more circulating tumor cells (at the first follow-up visit after initiation of a new line of therapy)[29].
CTC: Circulating tumor cell.
Figure 7 Kaplan-Meier estimates of probabilities of overall survival in patients with metastatic breast cancer who had less than 5 circulating tumor cells and those who had 5 or more circulating tumor cells (at the first follow-up visit after initiation of a new line of therapy)[29].
CTC: Circulating tumor cell.
Figure 8 Study design of the Southwest Oncology Group Trial S0500.
CTC: Circulating tumor cell.
Figure 9 Circulating tumor cell values at 8:00 AM and at 8:00 PM in the 51 assessable patients[36].
CTC: Circulating tumor cell.
- Citation: Park Y, Kitahara T, Urita T, Yoshida Y, Kato R. Expected clinical applications of circulating tumor cells in breast cancer. World J Clin Oncol 2011; 2(8): 303-310
- URL: https://www.wjgnet.com/2218-4333/full/v2/i8/303.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i8.303